We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down
Read MoreHide Full Article
Puma Biotechnology, Inc. (PBYI - Free Report) announced that it has signed a license agreement with the French pharmaceutical company Pierre Fabre, giving the latter the exclusive rights to develop/commercialize Nerlynx (neratinib) in Europe and across parts of Africa.
Nerlynx is approved as an extended adjuvant treatment of HER2-positive early stage breast cancer in adult patients, previously treated with Roche’s (RHHBY - Free Report) Herceptin-based adjuvant therapy. The drug was approved in Europe last September.
Per the agreement, Puma Biotech is eligible to receive an upfront payment of $60 million and up to $345 million in regulatory milestones plus double-digit royalties on Nerlynx sales. Pierre Fabre will enjoy exclusive marketing rights to Nerlynx in the European countries excluding Russia and Ukraine. Going forward, the French company will also be responsible for conducting additional clinical studies for Nerlynx label expansion in Europe.
However, it seems that the deal did not go down well with some investors and consequently, the stock took a hit. In fact, shares of Puma Biotech were down more than 8% following this news on Monday. However, the stock has soared 75.1% so far this year, outperforming the industry’s rally of 12.5%.
We would like to remind investors that Nerlynx was approved in the United States during July 2017. Sales of the drug have improved steadily since its launch and were above the management’s expectations last year. For 2018, Nerlynx generated sales of $200.5 million, slightly higher than the management’s guided range of $175-$200 million.
Several supplementary studies on Nerlynx targeting different types of breast cancer patient populations and in earlier-line settings are currently underway. Last month, Puma Biotech posted the updated interim results from the ongoing phase II SUMMIT basket study on Nerlynx for treating patients with HER2 mutated cervical cancer.
Outcomes from the study showed that treatment with Nerlynx led to durable responses and disease control in metastatic patients suffering HER2-mutant cervical cancer.
Apart from the HER2-positive breast cancer indication, the company believes that Nerlynx holds high potential for addressing several other cancers as well. The drug’s label expansion will thus allow treatment and access to an expanded subject count, thereby boosting its sales in the future.
Zacks Rank & Other Key Picks
Puma Biotech currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the healthcare sector include Kamada Ltd. and PDL BioPharma, Inc. (PDLI - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Kamada’s earnings estimates have moved 34.3% north for 2019 and 5% for 2020 over the past 60 days. The stock has risen 12.2% so far this year.
PDL BioPharma’s earnings estimates have moved 100% north for 2019 and 30% for 2020 over the past 60 days. The stock has gained 28.6% year to date.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down
Puma Biotechnology, Inc. (PBYI - Free Report) announced that it has signed a license agreement with the French pharmaceutical company Pierre Fabre, giving the latter the exclusive rights to develop/commercialize Nerlynx (neratinib) in Europe and across parts of Africa.
Nerlynx is approved as an extended adjuvant treatment of HER2-positive early stage breast cancer in adult patients, previously treated with Roche’s (RHHBY - Free Report) Herceptin-based adjuvant therapy. The drug was approved in Europe last September.
Per the agreement, Puma Biotech is eligible to receive an upfront payment of $60 million and up to $345 million in regulatory milestones plus double-digit royalties on Nerlynx sales. Pierre Fabre will enjoy exclusive marketing rights to Nerlynx in the European countries excluding Russia and Ukraine. Going forward, the French company will also be responsible for conducting additional clinical studies for Nerlynx label expansion in Europe.
However, it seems that the deal did not go down well with some investors and consequently, the stock took a hit. In fact, shares of Puma Biotech were down more than 8% following this news on Monday. However, the stock has soared 75.1% so far this year, outperforming the industry’s rally of 12.5%.
We would like to remind investors that Nerlynx was approved in the United States during July 2017. Sales of the drug have improved steadily since its launch and were above the management’s expectations last year. For 2018, Nerlynx generated sales of $200.5 million, slightly higher than the management’s guided range of $175-$200 million.
Several supplementary studies on Nerlynx targeting different types of breast cancer patient populations and in earlier-line settings are currently underway. Last month, Puma Biotech posted the updated interim results from the ongoing phase II SUMMIT basket study on Nerlynx for treating patients with HER2 mutated cervical cancer.
Outcomes from the study showed that treatment with Nerlynx led to durable responses and disease control in metastatic patients suffering HER2-mutant cervical cancer.
Apart from the HER2-positive breast cancer indication, the company believes that Nerlynx holds high potential for addressing several other cancers as well. The drug’s label expansion will thus allow treatment and access to an expanded subject count, thereby boosting its sales in the future.
Zacks Rank & Other Key Picks
Puma Biotech currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the healthcare sector include Kamada Ltd. and PDL BioPharma, Inc. (PDLI - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Kamada’s earnings estimates have moved 34.3% north for 2019 and 5% for 2020 over the past 60 days. The stock has risen 12.2% so far this year.
PDL BioPharma’s earnings estimates have moved 100% north for 2019 and 30% for 2020 over the past 60 days. The stock has gained 28.6% year to date.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>